Novo Nordisk | NVO - Equity Capital And Reserves


Novo Nordisk reported DKK26.56B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
ANI Pharmaceuticals USD 505.82M 69.06M Sep/2025
Aurora Cannabis CAD 567.1M 21.58M Sep/2025
Bausch Health Companies USD -554M 910M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 736.01M 247.04M Sep/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novo Nordisk DKK 194.05B 24.15B Dec/2025
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pacira USD 727.21M 30.55M Sep/2025
Perrigo USD 4.45B 25.8M Sep/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 1.83B 4.48M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
Zoetis USD 3.33B 2.07B Dec/2025